Arix Bioscience portfolio company VelosBio closes $137m Series B
Read more on VelosBio in this latest blog post by Arix Managing Director and VelosBio Board Director Jonathan Tobin
Tag Archive for: Series B
Azeria Therapeutics announces £32.0 million series B financing
Syncona leads £32.0 million Series B financing of Azeria Therapeutics with a £29.5 million commitment Opportunity to address a significant unmet need in oestrogen receptor positive breast cancer patients in lead programme and to build a world class pioneer factor oncology company London, 21 November 2019 – Azeria Therapeutics (Azeria), a newly formed pioneer factor […]
